Impact of vaginal estriol on serum hormone levels: a systematic review

References

• Portman DJ, Gass MLS, Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063–1068. doi: 10.1097/GME.0000000000000329.
   PubMed Web of Science ®Google Scholar
• Crean-Tate KK, Faubion SS, Pederson HJ, et al. Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy. Am J Obstet Gynecol. 2020;222(2):103–113. doi: 10.1016/j.ajog.2019.08.043.
   PubMed Web of Science ®Google Scholar
• Shim S, Park KM, Chung YJ, et al. Updates on therapeutic alternatives for genitourinary syndrome of menopause: hormonal and non-hormonal managements. J Menopausal Med. 2021;27(1):1–7. doi: 10.6118/jmm.20034.
   PubMedGoogle Scholar
• Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150. doi: 10.3109/13697137.2015.1129166.
   PubMed Web of Science ®Google Scholar
• “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of the North American Menopause Society. Menopause. 2022;29:767–794. doi: 10.1097/GME.0000000000002028.
   PubMed Web of Science ®Google Scholar
• Thiese MS. Observational and interventional study design types; an overview. Biochem Med (Zagreb). 2014;24(2):199–210. doi: 10.11613/BM.2014.022.
   PubMed Web of Science ®Google Scholar
• Nair B. Clinical trial designs. Indian Dermatol Online J. 2019;10(2):193–201. doi: 10.4103/idoj.IDOJ_475_18.
   PubMedGoogle Scholar
• Vieta E, Cruz N. Head to head comparisons as an alternative to placebo-controlled trials. Eur Neuropsychopharmacol. 2012;22(11):800–803. doi: 10.1016/j.euroneuro.2011.11.011.
   PubMed Web of Science ®Google Scholar
• Luisi M, Franchi F, Kicovic PM. A group-comparative study of effects of Ovestin cream versus Premarin cream in post-menopausal women with vaginal atrophy. Maturitas. 1980;2(4):311–319. doi: 10.1016/0378-5122(80)90033-x.
   PubMed Web of Science ®Google Scholar
• Sánchez-Rovira P, Hirschberg AL, Gil-Gil M, et al. A phase II prospective, randomized, double-blind, placebo-controlled and multicenter clinical trial to assess the safety of 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitor in the adjuvant setting. Oncologist. 2020;25(12):e1846-1854–e1854. doi: 10.1634/theoncologist.2020-0417.
   PubMed Web of Science ®Google Scholar
• Hirschberg AL, Sánchez-Rovira P, Presa-Lorite J, et al. Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial. Menopause. 2020;27(5):526–534. doi: 10.1097/GME.0000000000001497.
   PubMed Web of Science ®Google Scholar
• Wesel S, Etienne J, Lestienne MC. Clinical, cytological and biological study of the intra-vaginal administration of oestriol (Ortho-Gynest) in post-menopausal patients. Maturitas. 1981;3(3-4):271–277. doi: 10.1016/0378-5122(81)90034-7.
   PubMed Web of Science ®Google Scholar
• Te West NID, Day RO, Hiley B, et al. Estriol serum levels in new and chronic users of vaginal estriol cream: a prospective observational study. Neurourol Urodyn. 2020;39(4):1137–1144. doi: 10.1002/nau.24331.
   PubMed Web of Science ®Google Scholar
• Hoz F-DL, Orozco-Gallego H. Estriol vs. Conjugated estrogens of equine origin in the treatment of the genitourinary syndrome of menopause, Ginecol. Obstet México. 2018;86:117–126.
   Google Scholar
• Haspels AA, Luisi M, Kicovic PM. Endocrinological and clinical investigations in post-menopausal women following administration of vaginal cream containing oestriol. Maturitas. 1981;3(3–4):321–327. doi: 10.1016/0378-5122(81)90041-4.
   PubMed Web of Science ®Google Scholar
• Biglia N, Peano E, Sgandurra P, et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol. 2010;26(6):404–412. doi: 10.3109/09513591003632258.
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Diamant A, Santoro N. Safety of vaginal estrogens: a systematic review. Menopause. 2020;27(3):339–360. doi: 10.1097/GME.0000000000001468.
   PubMed Web of Science ®Google Scholar
• Te West N, Day R, Graham G, et al. Serum concentrations of estriol vary widely after application of vaginal oestriol cream. Br J Clin Pharmacol. 2021;87(5):2354–2360. doi: 10.1111/bcp.14635.
   PubMed Web of Science ®Google Scholar
• Rueda C, Osorio AM, Avellaneda AC, et al. The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. Climacteric. 2017;20(4):321–330. doi: 10.1080/13697137.2017.1329291.
   PubMed Web of Science ®Google Scholar
• Kicovic PM, Cortes-Prieto J, Milojević S, et al. The treatment of postmenopausal vaginal atrophy with Ovestin vaginal cream or suppositories: clinical, endocrinological and safety aspects. Maturitas. 1980;3(3-4):321–327. doi: 10.1016/0378-5122(80)90029-8.
   Google Scholar
• Donders G, Neven P, Moegele M, et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study, Breast Cancer. Breast Cancer Res Treat. 2014;145(2):371–379. doi: 10.1007/s10549-014-2930-x.
   PubMed Web of Science ®Google Scholar
• Pfeiler G, Glatz C, Königsberg R, et al. Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric. 2011;14(3):339–344. doi: 10.3109/13697137.2010.529967.
   PubMed Web of Science ®Google Scholar
• Pavlović RT, Janković SM, Milovanović JR, et al. The safety of local hormonal treatment for vulvovaginal atrophy in women with estrogen receptor-positive breast cancer who are on adjuvant aromatase inhibitor therapy: meta-analysis. Clin Breast Cancer. 2019;19(6):e731–e740. doi: 10.1016/j.clbc.2019.07.007.
   PubMed Web of Science ®Google Scholar
• Mattsson LA, Cullberg G. A clinical evaluation of treatment with estriol vaginal cream versus suppository in postmenopausal women. Acta Obstet Gynecol Scand. 1983;62(5):397–401. doi: 10.3109/00016348309154209.
   PubMed Web of Science ®Google Scholar
• de Oliveira Filho RV, Antunes NDJ, Ilha JDO, et al. Pharmacokinetics and pharmacodynamics of three dosages of oestriol after continuous vaginal ring administration for 21 days in healthy, postmenopausal women. Br J Clin Pharmacol. 2019;85(3):551–562. doi: 10.1111/bcp.13822.
   PubMed Web of Science ®Google Scholar
• Delgado JL, Estevez J, Radicioni M, et al. Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women. Climacteric. 2016;19(2):172–180. doi: 10.3109/13697137.2015.1098609.
   PubMed Web of Science ®Google Scholar
• Buhling KJ, Eydeler U, Borregaard S, et al. Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries. Arzneimittelforschung. 2012;62(8):378–383. doi: 10.1055/s-0032-1314822.
   PubMed Web of Science ®Google Scholar
• Batra S, Iosif S. Progesterone receptors in vaginal tissue of post-menopausal women. Maturitas. 1987;9(1):87–93. doi: 10.1016/0378-5122(87)90056-9.
   PubMed Web of Science ®Google Scholar
• Keller PJ, Riedmann R, Fischer M, et al. Oestrogens, gonadotropins and prolactin after intra-vaginal administration of oestriol in post-menopausal women. Maturitas. 1981;3(1):47–53. doi: 10.1016/0378-5122(81)90019-0.
   PubMed Web of Science ®Google Scholar
• Heimer G, Englund D. Estriol: absorption after long-term vaginal treatment and gastrointestinal absorption as influenced by a meal. Acta Obstet Gynecol Scand. 1984;63(6):563–567. doi: 10.3109/00016348409156720.
   PubMed Web of Science ®Google Scholar
• Heimer GM, Englund DE. Plasma oestriol following vaginal administration: morning versus evening insertion and influence of food. Maturitas. 1986;8(3):239–243. doi: 10.1016/0378-5122(86)90031-9.
   PubMed Web of Science ®Google Scholar
• Punnonen R, Vilska S, Grönroos M, et al. The vaginal absorption of oestrogens in post-menopausal women. Maturitas. 1980;2(4):321–326. doi: 10.1016/0378-5122(80)90034-1.
   PubMed Web of Science ®Google Scholar
• Mattsson LA, Cullberg G. Vaginal absorption of two estriol preparations. A comparative study in postmenopausal women. Acta Obstet Gynecol Scand. 1983;62(5):393–396. doi: 10.3109/00016348309154208.
   PubMed Web of Science ®Google Scholar
• van Haaften M, Donker GH, Haspels AA, et al. Oestrogen concentrations in plasma, endometrium, myometrium and vagina of postmenopausal women, and effects of vaginal oestriol (E3) and oestradiol (E2) applications. J Steroid Biochem. 1989;33(4A):647–653. doi: 10.1016/0022-4731(89)90055-1.
   PubMedGoogle Scholar
• Taylor HS, Pal L, Sell E. Speroff’s clinical gynecologic endocrinology and infertility. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2019.
   Google Scholar
• Center for Drug Evaluation and Research. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms—recommendations for clinical evaluation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estrogen-and-estrogenprogestin-drug-products-treat-vasomotor-symptoms-and-vulvar-and-vaginal-atrophy.
   Google Scholar
• European Medicines Agency. Clinical investigation of medicinal products for hormone replacement therapy oestrogen deficiency symptoms in postmenopausal women - scientific guideline. European Medicines Agency. 2006. https://www.ema.europa.eu/en/clinical-investigation-medicinal-products-hormone-replacement-therapy-oestrogen-deficiency-symptoms.
   Google Scholar
• Mitchell CM, Larson JC, Crandall CJ, et al. Association of vaginal estradiol tablet with serum estrogen levels in women who are postmenopausal: secondary analysis of a randomized clinical trial. JAMA Netw Open. 2022;5(11):e2241743. doi: 10.1001/jamanetworkopen.2022.41743.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric. 2005;8(1):83–92. doi: 10.1080/13697130500087016.
   PubMed Web of Science ®Google Scholar
• Del Pup L, Postruznik D, Corona G. Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: a pilot study. Maturitas. 2012;72(1):93–94. doi: 10.1016/j.maturitas.2012.01.017.
   PubMed Web of Science ®Google Scholar